Dinucleotide polymorphism of p73 gene is associated with a reduced risk of lung cancer in a Chinese population

International Journal of Cancer

Volumn 114, Issue 3, 2005, Pages 455-460

  Hu, Zhibin ^a   Miao, Xiaoping ^b   Ma, Hongxia ^a   Tan, Wen ^b   Wang, Xinru ^a   Lu, Daru ^c   Wei, Qingyi ^d   Lin, Dongxin ^b   Shen, Hongbing ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

^b CANCER HOSPITAL   (China)

^c FUDAN UNIVERSITY   (China)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Genetic susceptibility; Lung cancer; Molecular epidemiology; p73; Polymorphisms

Indexed keywords

PROTEIN P73;

5' UNTRANSLATED REGION; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CANCER PATIENT; CANCER RISK; CANCER SUSCEPTIBILITY; CASE CONTROL STUDY; CHINA; CONFIDENCE INTERVAL; CONTROLLED STUDY; DNA POLYMORPHISM; EXON; FEMALE; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENETIC RISK; GENETIC VARIABILITY; HAPLOTYPE; HETEROZYGOTE; HOMOZYGOSITY; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; POPULATION RESEARCH; PRIORITY JOURNAL; RISK ASSESSMENT;

AGED; BASE SEQUENCE; CASE-CONTROL STUDIES; CHINA; DNA-BINDING PROTEINS; FEMALE; GENES, TUMOR SUPPRESSOR; HUMANS; LINKAGE DISEQUILIBRIUM; LUNG NEOPLASMS; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; NUCLEAR PROTEINS; ODDS RATIO; POLYMORPHISM, GENETIC; RISK FACTORS; TUMOR SUPPRESSOR PROTEINS;

EID: 14044259992     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.20746     Document Type: Article

References (32)

1. International Agency for Research on Cancer. Tobacco Smoke and Involuntary Smoking. IARC monographs on the evaluation of carcinogenic risks to humans, vol. 83. Lyon: IARC, 2003.
2. Yang L, Parkin DM, Li L, Chen Y. Time trends in cancer mortality in China: 1987-1999. Int J Cancer 2003;106:771-83.
3. American Cancer Society, Inc. Cancer facts and figures 2003. Atlanta, GA: American Cancer Society, 2003.
4. Zhou BB, Elledge SJ. The DNA damage response: putting checkpoints in perspective. Nature 2000;408:433-9.
5. Wei Q, Cheng L, Hong WK, Spitz MR. Reduced DNA repair capacity in lung cancer patients. Cancer Res 1996;56:4103-7.
6. Wei Q, Cheng L, Amos CI, Wang LE, Guo Z, Hong WK, Spitz MR. Repair of tobacco carcinogen-induced DNA adducts and lung cancer risk: a molecular epidemiologic study. J Natl Cancer Inst 2000;92:1764-72.
7. Spitz MR, Wu X, Wang Y, Wang LE, Shete S, Amos CI, Guo Z, Lei L, Mohrenweiser H, Wei Q. Modulation of nucleotide excision repair capacity by XPD polymorphisms in lung cancer patients. Cancer Res 2001;61:1354-7.
8. Zheng Y, Shen H, Sturgis EM, Wang LE, Eicher SA, Strom SS, Frazier ML, Spitz MR, Wei Q. Cyclin D1 polymorphism and risk for squamous cell carcinoma of the head and neck: a case-control study. Carcinogenesis 2001;22:1195-9.
9. Matakidou A, Eisen T, Houlston RS. TP53 polymorphisms and lung cancer risk: a systematic review and meta-analysis. Mutagenesis 2003;18:377-85.
10. Kaghad M, Bonnet H, Yang A, Creancier L, Biscan JC, Valent A, Minty A, Chalon P, Lelias JM, Dumont X, Ferrara P, McKeon F, et al. Monoallelically expressed gene related to p53 at Ip36, a region frequently deleted in neuroblastoma and other human cancers. Cell 1997;90:809-19.
11. Jost CA, Marin MC, Kaelin WG Jr. p73 is a simian [correction of human] p53-related protein that can induce apoptosis. Nature 1997; 389:191-4.
12. Zhu J, Jiang J, Zhou W, Chen X. The potential tumor suppressor p73 differentially regulates cellular p53 target genes. Cancer Res 1998; 58:5061-5.
13. Wang XQ, Ongkeko WM, Lau AW, Leung KM, Poon RY. A possible role of p73 on the modulation of p53 level through MDM2. Cancer Res 2001;61:1598-603.
14. Cai YC, Yang GY, Nie Y, Wang LD, Zhao X, Song YL, Seril DN, Liao J, Xing EP, Yang CS. Molecular alterations of p73 in human esophageal squamous cell carcinomas: loss of heterozygosity occurs frequently; loss of imprinting and elevation of p73 expression may be related to detective p53.Carcinogenesis 2000;21:683-9.
15. Mai M, Yokomizo A, Qian C, Yang P, Tindall DJ, Smith DI, Liu W. Activation of p73 silent allele in lung cancer. Cancer Res 1998;58: 2347-9.
16. Nomoto S, Haruki N, Kondo M, Konishi H, Takahashi T, Takahashi T, Takahashi T. Search for mutations and examination of allelic expression imbalance of the p73 gene at 1p36.33 in human lung cancers. Cancer Res 1998;58:1380-3.
17. Ryan BM, McManus R, Daly JS, Carton E, Keeling PW, Reynolds JV, Kelleher D. A common p73 polymorphism is associated with a reduced incidence of oesophageal carcinoma. Br J Cancer 2001;85: 1499-503.
18. Hamajima N, Matsuo K, Suzuki T, Nakamura T, Matsuura A, Hatooka S, Shinoda M, Kodera Y, Yamamura Y, Hirai T, Kato T, Tajima K. No associations of p73 G4C14-to-A4T14 at exon 2 and p53 Arg72Pro polymorphisms with the risk of digestive tract cancers in Japanese. Cancer Lett 2002;181:81-5.
19. Huang XE, Hamajima N, Katsuda N, Matsuo K, Hirose K, Mizutani M, Iwata H, Miura S, Xiang J, Tokudome S, Tajima K. Association of p53 codon Arg72Pro and p73 G4C14-to-A4T14 at exon 2 genetic polymorphisms with the risk of Japanese breast cancer. Breast Cancer 2003;10:307-11.
20. Hiraki A, Matsuo K, Hamajima N, Ito H, Hatooka S, Suyama M, Mitsudomi T, Tajima K. Different risk relations with smoking for non-small-cell lung cancer: comparison of TP53 and TP73 genotypes. Asian Pac J Cancer Prev 2003;4:107-12.
21. Niwa Y, Hamajima N, Atsuta Y, Yamamoto K, Tamakoshi A, Saito T, Hirose K, Nakanishi T, Nawa A, Kuzuya K, Tajima K. Genetic polymorphisms of p73 G4C14-to-A4T14 at exon 2 and p53 Arg72Pro and the risk of cervical cancer in Japanese. Cancer Lett 2004;205:55-60.
22. Barrett MT, Sanchez CA, Prevo LJ, Wong DJ, Galipeau PC, Paulson TG, Rabinovitch PS, Reid BJ. Evolution of neoplastic cell lineages in Barrett oesophagus. Nat Genet 1999;22:106-9.
23. Stiewe T, Zimmermann S, Frilling A, Esche H, Putzer BM. Transactivation-deficient DeltaTA-p73 acts as an oncogene. Cancer Res 2002; 62:3598-602.
24. Sayan AE, Sayan BS, Findikli N, Ozturk M. Acquired expression of transcriptionally active p73 in hepatocellular carcinoma cells. Oncogene 2001;20:5111-7.
25. Grob TJ, Novak U, Maisse C, Barcaroli D, Luthi AU, Pirnia F, Hugli B, Graber HU, De Laurenzi V, Fey MF, Melino G, Tobler A. Human delta Np73 regulates a dominant negative feedback loop for TAp73 and p53. Cell Death Differ. 2001;8:1213-23.
26. Ishimoto O, Kawahara C, Enjo K, Obinata M, Nukiwa T, Ikawa S. Possible oncogenic potential of DeltaNp73: a newly identified isoform of human p73. Cancer Res 2002;62:636-41.
27. Zaika AI, Slade N, Erster SH, Sansome C, Joseph TW, Pearl M, Chalas E, Moll UM. DeltaNp73, a dominant-negative inhibitor of wild-type p53 and TAp73, is up-regulated in human tumors. J Exp Med 2002;196:765-80.
28. Concin N, Becker K, Slade N, Erster S, Mueller-Holzner E, Ulmer H, Daxenbichler G, Zeimet A, Zeillinger R, Marth C, Moll UM. Transdominant DeltaTAp73 isoforms are frequently up-regulated in ovarian cancer. Evidence for their role as epigenetic p53 inhibitors in vivo. Cancer Res 2004;64:2449-60.
29. O'Nions J, Brooks LA, Sullivan A, Bell A, Dunne B, Rozycka M, Reddy A, Tidy JA, Evans D, Farrell PJ, Evans A, Gasco M, et al. p73 is over-expressed in vulval cancer principally as the Delta 2 isoform. Br J Cancer 2001;85:1551-6.
30. Stiewe T, Tuve S, Peter M, Tannapfel A, Elmaagacli AH, Putzer BM. Quantitative TP73 transcript analysis in hepatocellular carcinomas. Clin Cancer Res 2004;10:626-33.
31. Liu HX, Cartegni L, Zhang MQ, Krainer AR. A mechanism for exon skipping caused by nonsense or missense mutations in BRCA1 and other genes. Nat Genet 2001;27:55-8.
32. Hamajima N, Saito T, Matsuo K, Kozaki K, Takahashi T, Tajima K. Polymerase chain reaction with confronting 2-pair primers for polymorphism genotyping. Jpn J Cancer Res 2000;91:865-8.